Premium
The value of FDG‐PET in the staging of gastric adenocarcinoma: A single institution retrospective review
Author(s) -
Serrano Oscar K.,
Love Charito,
Goldman Inessa,
Huang Kevin,
Ng Nicole,
Abraham Tony,
Da Silva Raphaella,
Friedmann Patricia,
Libutti Steven K.,
Kennedy Timothy J.
Publication year - 2016
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24190
Subject(s) - medicine , stage (stratigraphy) , radiology , positron emission tomography , retrospective cohort study , adenocarcinoma , lymph node , biopsy , nuclear medicine , pet ct , standardized uptake value , cancer , paleontology , biology
Background The value of FDG‐PET in the staging of gastric adenocarcinoma (GA) has been subject to debate. Methods We performed a retrospective review of GA patients between 2006 and 2014 and identified those who had a CT and FDG‐PET before initiating treatment. CT and FDG‐PET images were analyzed by a blinded body radiologist and nuclear physician, respectively. Disease stage was assessed, looking at primary tumor (PT), locoregional (LLN) and distant lymph node disease (DLN), and metastasis (M). Results We identified 608 patients who had biopsy‐proven GA and 207 (34.0%) had a CT and FDG‐PET as part of their staging work‐up. Of these, imaging from 166 (27.3%) patients was available for review. CT identified PT, LLN, DLN, and M in 120 (72.3%), 84 (50.6%), 25 (15.1%), and 32 (19.3%) patients, respectively; while FDG‐PET identified PT, LLN, DLN, and M in 125 (75.3%), 78 (47.0%), 41 (24.7%), and 27 (16.3%) of patients, respectively. FDG‐PET up‐staged 31 (18.7%) patients while it down‐staged 17 (10.2%) patients. Of patients who were up‐staged, 20 (64.5%) developed progressive disease. Conclusions Our findings support the use of FDG‐PET as a valuable adjunct to CT in the staging of GA, as it changed the stage in 48 (28.9%) patients. J. Surg. Oncol. 2016;113:640–646 . © 2016 Wiley Periodicals, Inc.